STOCKS TELEGRAPH

Tag: Traws Pharma

  • Traws Pharma (TRAW) Stock Skyrockets In After-Hour Trading

    Traws Pharma (TRAW) Stock Skyrockets In After-Hour Trading

    Shares of Traws Pharma, Inc. (NASDAQ: TRAW) experienced a significant surge last Friday, rising by 57.57% during after-hours trading to reach $12.70. The dramatic spike came after the business made a ground-breaking disclosure on its H5N1 antiviral program, highlighting the promise of its experimental medication, Tivoxavir Marboxil.

    Promising Results from a Novel Antiviral Drug

    A hybrid AI-powered drug discovery and development accelerator called Promising Results from a Novel Antiviral Drug Expert Systems was important in reaching this milestone. Preclinical and clinical outcomes for Tivoxavir Marboxil, an oral cap-dependent endonuclease inhibitor created in partnership with Traws Pharma, were promising.

    The medication has broad-spectrum effectiveness against a variety of flu strains, including highly pathogenic and drug-resistant avian flu viruses, by targeting a highly conserved influenza protein. In a Phase 1 clinical trial involving healthy, influenza-negative adult volunteers, Tivoxavir Marboxil showcased a strong safety profile with no treatment-related adverse effects.

    Its promise as a one-time therapy for H5N1 avian influenza is suggested by the fact that a single dosage kept plasma drug levels above the effective concentration (EC90) for more than 23 days.

    Addressing the Growing Threat of Avian Influenza

    The increasing prevalence of H5N1 avian influenza in wild and domestic animals, along with recent human infections and severe cases, has heightened concerns about the virus’s potential to adapt to humans. Such adaptations could lead to widespread outbreaks or pandemics, underlining the urgent need for effective treatments like Tivoxavir Marboxil.

    Expert Systems’ innovative approach, combining artificial intelligence with human expertise, has been instrumental in accelerating the development of this groundbreaking antiviral therapy. Their collaboration with Traws Pharma exemplifies how technology-driven solutions can expedite critical advancements in global health.

    Looking Ahead: Phase 2 Trials on the Horizon

    With the successful completion of Phase 1 trials, Traws Pharma is preparing to initiate Phase 2 efficacy studies in the first half of 2025. This marks a significant step toward making Tivoxavir Marboxil a viable treatment option for H5N1 bird flu, addressing an urgent need in combating this global health threat. The drug’s success underscores the transformative potential of AI-driven drug development in tackling pressing public health challenges.

  • Traws Pharma (TRAW) Shares Jump On Strong Trial Results

    Traws Pharma (TRAW) Shares Jump On Strong Trial Results

    The stock price of Traws Pharma, Inc. (NASDAQ: TRAW) has experienced a notable increase, with shares rising by 143.03% to $12.20 in midday trade. This increase comes after the business revealed encouraging top-line findings from its Phase 1 clinical study of tivoxavir marboxil, an experimental one-dose treatment for H5N1 avian influenza or bird flu.

    Progress in Influenza Treatment Development

    Traws Pharma revealed encouraging developments in its efforts to address the growing global concern over avian influenza. Tivoxavir marboxil, a new therapeutic drug, has showed strong activity against numerous strains of the highly pathogenic H5N1 virus in preclinical tests.

    In lab experiments and animal models, the medication showed potent suppression of the virus, greatly increasing survival rates and lowering the viral load in infected mice. Given the growing number of reports of H5N1 infections in humans and wildlife, these findings are viewed as a positive step in the development of a cure.

    Promising Results of The Trials 

    In a randomized, double-blind, placebo-controlled research, the tivoxavir marboxil Phase 1 clinical trial evaluated the medication’s pharmacokinetics, safety, and tolerability in healthy adult participants. According to the first topline findings, a single dosage of the treatment kept plasma medication levels for more than 23 days significantly higher than the effective concentration required to fight the virus.

    The study’s safety profile was further validated by the noteworthy absence of treatment-related side events. Additionally, data from higher-dose cohorts are still pending, and further results are anticipated to enhance the therapeutic potential of tivoxavir marboxil.

    Future Outlook for Tivoxavir Marboxil

    Traws Pharma’s latest findings suggest significant potential for tivoxavir marboxil in combating the H5N1 bird flu, a disease that poses both a public health risk and an occupational hazard for those working in poultry and dairy industries. With rising concerns about the virus’s ability to adapt to humans and spread, the success of this investigational drug may offer a critical tool in the fight against future outbreaks, including the possibility of an epidemic or pandemic.